Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
J Antibiot (Tokyo). 2010 Apr;63(4):151-5. doi: 10.1038/ja.2010.9. Epub 2010 Feb 26.
The in vivo-mimic assay system using silkworm larvae was used as a screening tool to discover antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). Microbial culture broths were screened in this in vivo-mimic assay system and a culture broth of Streptomyces sp. K04-0144 was selected. New antibiotics, designated nosokomycins A-D, were isolated from the culture broth by HP-20 and ODS column chromatography and HPLC. Nosokomycins inhibited the growth of MRSA with MIC values of 0.125 microg ml(-1) using the liquid microdilution method. Furthermore, MRSA-infected silkworms survived when nosokomycin A or B was injected at a dose of 50 microg per larva.
采用家蚕幼虫体内模拟测定系统作为筛选工具，以发现针对耐甲氧西林金黄色葡萄球菌（MRSA）的抗生素。在该体内模拟测定系统中筛选微生物培养液，选择了一株链霉菌属 K04-0144 的培养液。采用 HP-20 和 ODS 柱层析和 HPLC 从该培养液中分离出新型抗生素，命名为 nosokomycins A-D。采用液体微量稀释法，nosokomycins 的 MIC 值为 0.125μgml（-1），抑制了 MRSA 的生长。此外，当以每头幼虫 50μg 的剂量注射 nosokomycin A 或 B 时，感染 MRSA 的家蚕幼虫存活。
